Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluconazole + azithromycin + secnidazole is a fixed-dose combination (FDC) anti-infective therapy developed by Chem Med Pharmaceuticals for the treatment of mixed vaginal infections. This 'combikit' approach is designed for the syndromic management of vaginal discharge, addressing fungal, bacterial, and protozoal pathogens simultaneously. Fluconazole, a triazole antifungal, inhibits the enzyme lanosterol 14-alpha demethylase, disrupting fungal cell membrane synthesis. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Secnidazole is a nitroimidazole derivative that enters the cell and is reduced to intermediates that cause DNA strand breakage, effectively treating anaerobic bacteria and protozoa like Trichomonas vaginalis. The combination is typically administered as a single-day oral regimen to ensure high patient compliance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluconazole + azithromycin + secnidazole.